Comparison of Efficacy and Safety Between Aspirin and Cilostazol on Cardiovascular Event in Patients at High Risk of Cardiovascular Disease, Randomization.
Patients with type 2 diabetes and cardiovascular risk factors are at increased risk of cardiovascular events. Therefore, a multi-center prospective randomized study will be conducted to compare the efficacy and safety of cilostazol and aspirin for the prevention of major adverse cardiac and cerebrovascular events (MACCE) in high-risk patients with type 2 diabetes.
• Individuals with type 2 diabetes mellitus were eligible if they were aged ≥19 years
• Individuals with subclinical atherosclerosis or metabolic syndrome, defined as at least one of the following:
• Carotid intima-media thickness ≥ 1 mm
• Ankle-brachial index \< 0.9 - Pulse wave velocity ≥ 9 m/s
• Flow-mediated vasodilatation \< 5%
• Coronary artery calcium score ≥ 40
• Coronary artery stenosis ≥ 20% or ≤ 70%
• Peripheral artery occlusive disease ≥ 20%
• Metabolic syndrome
• Individuals with HbA1c ≤ 9.9%
• Individuals who voluntarily agree to participate in the study and provide written informed consent